Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

CTSO - Hire Sounds Like a Perfect Fit

Brian Marckx, CFA
 
CytoSorbents (OTC BB:(CTSO) continues to make meaningful progress with its measured roll-out of CytoSorb in Europe which includes making key additions to its sales and marketing team.  CTSO's CEO, Phil Chan, recently noted that the company would be very discerning in who they choose to fill the ranks of their sales force.  

The background of the most recent addition, announced this morning, appears to be a perfect fit for what Dr. Chan is looking for, specifically highly experience with a track record of success in their target segments.  The recent hire, Dr. Christian Steiner, a medical doctor educated in Europe, has direct and relevant experience in selling novel critical care extracorporeal devices to the ICU channel - essentially, the same thing CytoSorbents' is trying to do.

Per this morning's press release on Dr. Steiner's background, "Christian brings 12 years of experience introducing new technologies to the intensive care unit, starting with the Molecular Adsorbent Recirculation System, better known as MARS™, the most used extracorporeal liver support system in ICU patients with liver failure today."
 
Dr. Steiner's title will be VP of Sales and Marketing.  He will be in charge of CytoSorbents' European sales and distribution arm, which opened earlier this year and is the base for the European sales operation.

Key to a successful initial launch of CytoSorb will be to build awareness via investigator-led studies, getting the device in front of influential industry leaders and targeting early adopters.  We presume Dr. Steiner's background and experience also means he comes armed with potentially key industry contacts and relationships (including in the initial markets in Europe) which he and the rest of the sales team can leverage to increase awareness of CytoSorb and build sales momentum.

We picked up Coverage of CTSO in early June with an Outperform rating and $0.50 price target.  Please visit scr.zacks.com to access our 21-page initiation report.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%